Clinical Trial Update: A Phase I, Study to Evaluate the Safety and Tolerability of Intravenous EZN-2208 in Patients With Advanced Solid Tumors or Lymphoma (EZN-2208-02) [Phase 1]

View source ↗

Summary

A Phase I study evaluating the safety and tolerability of EZN-2208 in patients with lymphoma or advanced solid tumors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Solid Tumors

Drugs mentioned

• EZN-2208

Snippet

Sponsor: Enzon Pharmaceuticals, Inc. | Conditions: Lymphoma, Advanced Solid Tumors | Phase 1 | Status: COMPLETED